Marketing Manager
About the job
- A bachelor's degree or above, majoring in Medical or Medicine.
- Good command of spoken and written English.
- Five to eight years of marketing experience, including more than twelve months of SBM experience.
- Demonstrated ability in market, customer, and competitor insight; strategic and operational business and market planning; market execution; marketing innovation; data analysis, interpretation, and communication; and performance and program metrics.
- Demonstrate functional and technical skills, decisive action, accountability, self-development, adaptability to change, self-awareness, and peer relationship skills.
- Own portfolio or big strategic brand strategy to maximize franchise business and achieve earnings and revenue objectives.
- Define and drive portfolio or big strategic brand strategy, growth, and lifecycle management; forecast revenue and operating expenses; and ensure revenue and profitability targets are achieved in China.
- Interface with medical, GAMA, and other functions as a supporter.
- Assist the Marketing Lead in building marketing capabilities of the product management team to improve business effectiveness and efficiency.
- Translate brand strategies into plans of action for the responsible brand as a supporter.
- Execute brand tactics and independently manage projects, including managing budgets, setting key performance indicators, tracking progress, and resolving issues.
- Develop brand detail aids, promotional slides, publications as needed, and internal training materials.
- Train the field force on product strategy and plans of action.
- Analyze market trends and competitor situations to support brand strategy development.
- Explore customer insights and brand value propositions to support brand strategy development.
- Timely track progress toward brand targets.
- Support cross-functional brand leadership across field force, account management, medical, legal, and regulatory teams.
- Ensure flawless execution of marketing activities and independently manage projects.
- Conduct sales training and actively participate in campaign development.
- Support business planning and operational planning, influence sales targets and brand advertising and promotion allocations, develop the marketing mix and plans of action, and interface with cross-functional teams.
About the company
Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.
Company Size
10,001+
Company Stage
IPO
Headquarters
New York City, New York
Founded
1849
Get referred to Pfizer
See people who can refer or advise you
Simplify's Take
What believers are saying
- Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
- The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
- Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.
What critics are saying
- Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
- Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
- Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.
What makes Pfizer unique
- Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
- Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
- Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Relocation Assistance
Growth & Insights and Company News
6 month growth
-4%1 year growth
-3%2 year growth
-3%High dividend yields can hide weak payouts, and a four-step test helps separate real income from traps. It checks earnings with one-offs stripped out, full-year free cash flow against dividends, management's explanation, and whether debt funds the gap. Ford yields 4.99% and shows a trailing EPS of -$1.88, caused by $4.2B in one-time charges. Its debt-to-equity of 4.66 leaves the $0.60 dividend exposed to a downturn. Pfizer yields 6.03%, but its free cash flow yield is 5.60%. Clorox's roughly $405M of free cash flow fell short of about $601M in dividends. Whirlpool fails every step. It cut its quarterly dividend from $1.75 to $0.90 in 2025, paid no common dividend in the second quarter of 2026, and its shares are down 59.48% since the end of 2025. 3M and Dow pass, with payouts now covered by cash.
Four blue chip companies, UPS, Pfizer, Kraft Heinz, and Ford, may struggle to sustain their dividends, according to an analysis of their earnings, cash flow, and debt. UPS yields 7.02% and pays out about 121% of its GAAP earnings. Pfizer yields 6.10%, with a GAAP payout ratio of about 226%; its 2025 free cash flow of $9.076 billion fell short of $9.771 billion in dividends. Kraft Heinz yields 6.82%, but its trailing GAAP earnings per share are −$2.88 after $7.4 billion in impairments. Ford yields 4.98% after an $8.162 billion loss in 2025, and its debt-to-equity ratio is 4.66. All four companies say their payouts are safe, and each points to adjusted earnings guidance that covers the dividend.
The FDA has approved Pfizer's TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab for front-line maintenance treatment of adults with HER2-positive metastatic breast cancer. This chemotherapy-free option expands TUKYSA's use to an earlier disease stage. The approval follows Phase 3 HER2CLIMB-05 trial results showing median progression-free survival of 24.9 months versus 16.3 months with placebo—8.6 additional months without disease progression. The treatment reduced risk of progression or death by 35.9%. Most common adverse events included diarrhoea, musculoskeletal pain, hepatotoxicity, nausea, fatigue, rash, and vomiting. One fatal case of drug-induced liver injury occurred. TUKYSA was previously approved for second-line HER2-positive metastatic breast cancer treatment in 2020. HER2 is overexpressed in 15-20% of breast cancers.
Warren Buffett's favourite valuation metric, the ratio of total market capitalisation to GDP, has reached 235.8%, well above the 200% level he warned constitutes "playing with fire". The indicator sits near its record high from September 2026. Despite elevated overall market valuations, three stocks remain attractively priced. Enterprise Products Partners trades at 11.9 times forward earnings whilst offering a 6% distribution yield, benefiting from increased natural gas demand from AI data centres. JPMorgan Chase trades at 13.5 times forward earnings and could benefit from rising interest rates. Pfizer trades at just 9.7 times forward earnings with a 6.3% dividend yield, though it faces patent cliff challenges through 2028.
Vaxcyte announced its 31-valent pneumococcal vaccine, VAX-31, met all primary endpoints in a Phase 3 trial with 4,047 participants. The vaccine matched Pfizer's Prevnar 20 on all 20 shared serotypes and Merck's Capvaxive on 17 of 19 shared serotypes. Pfizer's Prevnar franchise generated $6.49 billion in 2025, representing roughly 10% of the company's $62.58 billion total revenue. The franchise grew just 1% last year, with Pfizer citing lower US market share. Merck's Capvaxive brought in $759 million in 2025, about 1% of its revenue. Pfizer trades at 9.87x forward earnings whilst Merck trades at 16.36x. Vaxcyte plans to file for approval in the first half of 2028. The company expects results from two additional trials in the first half of 2027.